Skip to main content
SpringerLink
Log in

Pathophysiologie: Mikrobiom

  • Chapter
  • First Online:
Nicht-alkoholische Fettlebererkrankung

  • 1013 Accesses

Zusammenfassung

Das intestinale Mikrobiom ist Teil der „Darm-Leber Achse“, die die physiologische Verbindung zwischen Darm und Leber darstellt. Bei der Pathogenese der nicht-alkoholischen Fettlebererkrankung (NAFLD) spielt das intestinale Mikrobiom eine besondere Rolle, da über die Pfortader Botenstoffe aus dem Darm zur Leber gelangen und dort inflammatorische oder metabolische Prozesse beeinflussen. Veränderungen in der Zusammensetzung des intestinalen Mikrobioms wurden bei NAFLD-Patienten auf Phylum-, Familien-, Gattungs- und Speziesebene beschrieben. Die bisherigen Studien weisen darauf hin, dass bei der NAFLD ebenso wie bei Adipositas und Diabetes mellitus Typ 2 eine krankheitsspezifische Signatur im intestinalen Mikrobiom zu finden ist. Das intestinale Mikrobiom stellt mit seinen vielseitigen Angriffspunkten, d. h. der Zusammensetzung, den bakteriellen Stoffwechselprodukten und den immunologischen Effekten ein spannendes Netzwerk dar, das zukünftig für die Diagnostik und Therapie von großem Interesse sein wird. Um die bisherigen Ergebnisse dauerhaft in den klinischen Alltag einzuführen, werden jedoch weitere standardisierte Studien bei NAFLD Patienten benötigt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Abenavoli L, Di Renzo L, Boccuto L et al (2018) Health benefits of Mediterranean diet in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 12:873–881

    Article  CAS  PubMed  Google Scholar 

  • Alisi A, Manco M, Devito R et al (2010) Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 50:645–649

    Article  CAS  PubMed  Google Scholar 

  • Aller R, De Luis DA, Izaola O et al (2011) Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 15:1090–1095

    CAS  PubMed  Google Scholar 

  • Backhed F, Ding H, Wang T et al (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101:15718–15723

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bjorkholm B, Bok CM, Lundin A et al (2009) Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS ONE 4:

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Boursier J, Mueller O, Barret M et al (2015) The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology (Baltimore, Md.)

    Google Scholar 

  • Bundgaard-Nielsen C, Hagstrom S, Sorensen S (2018) Interpersonal variations in gut microbiota profiles supersedes the effects of differing fecal storage conditions. Scientific Reports 8:17367

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Caussy C, Hsu C, Lo MT et al (2018) Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology (Baltimore, Md.) 68:918–932

    Google Scholar 

  • Caussy C, Tripathi A, Humphrey G et al (2019) A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun 10:1406

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Cho MS, Kim SY, Suk KT et al (2018) Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol 56:855–867

    Article  CAS  PubMed  Google Scholar 

  • Cobbold JFL, Atkinson S, Marchesi JR et al (2018) Rifaximin in non-alcoholic steatohepatitis: an open-label pilot study. Hepatol Res Official J Japan Soc Hepatol 48:69–77

    Article  CAS  Google Scholar 

  • D’argenio V, Salvatore F (2015) The role of the gut microbiome in the healthy adult status. Clinica chimica acta; Int J Clin Chem 451:97–102

    Google Scholar 

  • Daubioul CA, Horsmans Y, Lambert P et al (2005) Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr 59:723–726

    Article  CAS  PubMed  Google Scholar 

  • De Faria Ghetti F, Oliveira DG, De Oliveira JM et al (2018) Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr 57:861–876

    Article  CAS  Google Scholar 

  • Del Chierico F, Nobili V, Vernocchi P et al (2017) Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology (Baltimore, Md.) 65:451–464

    Google Scholar 

  • Drenick EJ, Fisler J, Johnson D (1982) Hepatic steatosis after intestinal bypass–prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 82:535–548

    Article  CAS  PubMed  Google Scholar 

  • Fleissner CK, Huebel N, Abd El-Bary MM et al (2010) Absence of intestinal microbiota does not protect mice from diet-induced obesity. British J Nutr 104:919–929

    Article  CAS  Google Scholar 

  • Forslund K, Hildebrand F, Nielsen T et al (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528:262–266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Grabherr F, Grander C, Effenberger M et al (2019) Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Front Endocrinol 10:611

    Article  Google Scholar 

  • Hoyles L, Fernandez-Real JM, Federici M et al (2018) Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med 24:1070–1080

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jiang W, Wu N, Wang X et al (2015) Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Scientific Reports 5:8096

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Koh A, Molinaro A, Stahlman M et al (2018) Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1. Cell 175:947–961.e917

    Article  CAS  PubMed  Google Scholar 

  • Lambert JE, Parnell JA, Eksteen B et al (2015) Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol 15:169

    Article  PubMed  PubMed Central  Google Scholar 

  • Le Roy T, Llopis M, Lepage P et al (2013) Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62:1787–1794

    Article  PubMed  CAS  Google Scholar 

  • Letexier D, Diraison F, Beylot M (2003) Addition of inulin to a moderately high-carbohydrate diet reduces hepatic lipogenesis and plasma triacylglycerol concentrations in humans. Am J Clin Nutr 77:559–564

    Article  CAS  PubMed  Google Scholar 

  • Ley RE, Turnbaugh PJ, Klein S et al (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444:1022–1023

    Article  CAS  PubMed  Google Scholar 

  • Loomba R, Seguritan V, Li W et al (2017) Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 25:1054–1062.e1055

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Luther J, Garber JJ, Khalili H et al (2015) Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol 1:222–232

    Article  PubMed  PubMed Central  Google Scholar 

  • Malaguarnera M, Vacante M, Antic T et al (2012) Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 57:545–553

    Article  PubMed  Google Scholar 

  • Manzhalii E, Virchenko O, Falalyeyeva T et al (2017) Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial. J Dig Dis 18:698–703

    Article  CAS  PubMed  Google Scholar 

  • Michail S, Lin M, Frey MR et al (2015) Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol 91:1–9

    Article  PubMed  CAS  Google Scholar 

  • Mofidi F, Poustchi H, Yari Z et al (2017) Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. British J Nutr 117:662–668

    Article  CAS  Google Scholar 

  • Mouzaki M, Comelli EM, Arendt BM et al (2013) Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.) 58:120–127

    Google Scholar 

  • Penington JS, MaS Penno, Ngui KM et al (2018) Influence of fecal collection conditions and 16S rRNA gene sequencing at two centers on human gut microbiota analysis. Scientific Reports 8:4386

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Raman M, Ahmed I, Gillevet PM et al. (2013) Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol Official Clin Pract J Am Gastroenterolo Assoc 11:868–875.e861–863

    Google Scholar 

  • Rau M, Rehman A, Dittrich M et al (2018) Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United Eur Gastroenterol J 6:1496–1507

    Article  CAS  Google Scholar 

  • Reijnders D, Goossens GH, Hermes GD et al (2016) Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized Double-Blind Placebo-Controlled trial. Cell Metab 24:63–74

    Article  CAS  PubMed  Google Scholar 

  • Safari Z, Gerard P (2019) The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cellular and molecular life sciences: CMLS

    Google Scholar 

  • Safari Z, Gérard P (2019) The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 76:1541–1558

    Article  CAS  PubMed  Google Scholar 

  • Scorletti E, Afolabi PR, Miles EA et al (2020) Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease. Gastroenterology

    Google Scholar 

  • Spencer MD, Hamp TJ, Reid RW et al (2011) Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140:976–986

    Article  CAS  PubMed  Google Scholar 

  • Thuy S, Ladurner R, Volynets V et al (2008) Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 138:1452–1455

    Article  CAS  PubMed  Google Scholar 

  • Vajro P, Mandato C, Licenziati MR et al (2011) Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 52:740–743

    Article  PubMed  Google Scholar 

  • Verdam FJ, Rensen SS, Driessen A et al (2011) Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J Clin Gastroenterol 45:149–152

    Article  CAS  PubMed  Google Scholar 

  • Vrieze A, Van Nood E, Holleman F et al (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143:913–916.e917

    Article  CAS  PubMed  Google Scholar 

  • Wang B, Jiang X, Cao M et al (2016) Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Scientific reports 6:32002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wigg AJ, Roberts-Thomson IC, Dymock RB et al (2001) The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48:206–211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wong VW, Tse CH, Lam TT et al (2013) Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis–a longitudinal study. PLoS ONE 8:

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wu H, Esteve E, Tremaroli V et al (2017) Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 23:850–858

    Article  CAS  PubMed  Google Scholar 

  • Zhu L, Baker SS, Gill C et al (2013) Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology (Baltimore, Md.) 57:601–609

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik II, Schwerpunkt Hepatologie, Universitätsklinikum Würzburg, Würzburg, Deutschland

    Monika Rau

Authors
  1. Monika Rau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monika Rau .

Editor information

Editors and Affiliations

  1. Medizinische Klinik u. Poliklinik II, Universititätsklinikum Würzburg, ZIM, Würzburg, Bayern, Deutschland

    Andreas Geier

  2. Medizinische Klinik, Universitätsklinikum Bochum GmbH, Bochum, Deutschland

    Ali Canbay

  3. Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg, Saarland, Deutschland

    Frank Lammert

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rau, M. (2022). Pathophysiologie: Mikrobiom. In: Geier, A., Canbay, A., Lammert, F. (eds) Nicht-alkoholische Fettlebererkrankung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62484-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62484-5_9

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62483-8

  • Online ISBN: 978-3-662-62484-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation